Evidence map›Paper›PMID 37914738›Full record

ArticleNPJ vaccines2023

Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine.

Hirotaka Fukami, Jun Morinaga, Hironori Nakagami, Hiroki Hayashi, Yusuke Okadome, Eiji Matsunaga, Tsuyoshi Kadomatsu, Haruki Horiguchi, Michio Sato, Taichi Sugizaki and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Hirotaka FukamiDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.ORCID http://orcid.org/0000-0002-7375-0748
Jun MorinagaDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. morijun@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0002-6196-6023
Hironori NakagamiDepartment of Health Development and Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, 565-0871, Japan.ORCID http://orcid.org/0000-0003-4494-3601
Hiroki HayashiDepartment of Health Development and Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, 565-0871, Japan.
Yusuke OkadomeDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Eiji MatsunagaDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Tsuyoshi KadomatsuDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.ORCID http://orcid.org/0000-0003-3327-6954
Haruki HoriguchiDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Michio SatoDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Taichi SugizakiDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Keishi MiyataDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Daisuke TorigoeDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Masashi MukoyamaDepartment of Nephrology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan.
Ryuichi MorishitaDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita-shi, 565-0871, Japan.
Yuichi OikeDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, 860-8556, Japan. oike@gpo.kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0003-3245-5395
Kumamoto University · JPThe University of Osaka · JPKumamoto University Hospital · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP23ym0126809MEXT | Japan Society for the Promotion of Science (JSPS) 21K20935MEXT | Japan Society for the Promotion of Science (JSPS) 22K16429
6 · The paper itself

Abstract

Previously, we reported that an ANGPTL3 vaccine is a hopeful therapeutic option against dyslipidemia. In our current study, we assess durability and booster effects of that vaccine over a period representing a mouse's lifespan. The vaccine remained effective for over one year, and booster vaccination maintained suppression of circulating triglyceride levels thereafter without major adverse effects on lungs, kidneys, or liver, suggesting vaccine efficacy and safety.

Identifiers

PMID37914738
PMCPMC10620388
OpenAlexW4388140966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.